Press Releases

 
Press Releases
  Date Title and Summary View
Oct 23, 2008
Fremont, Calif. – October 23, 2008 – Zosano Pharma, Inc., a privately held pharmaceutical company developing a novel transdermal delivery technology for a broad range of therapeutic indications, announced today that John Vuko, Chief Financial Officer of Zosano will present at the 7th annual BIO Investor Forum. Mr. Vuko will...
Sep 11, 2008
Fremont, Calif. – September 11, 2008 – Zosano Pharma, Inc., a privately held pharmaceutical company developing a novel transdermal delivery technology, today announced that an abstract detailing results of its Phase 2 study of Zosano PTH Patch, a proprietary transdermal patch formulation of parathyroid hormone (PTH) for the tre...
Sep 8, 2008
Fremont, CA – September 8, 2008 – Zosano Pharma, Inc., a privately held pharmaceutical company developing a novel transdermal delivery technology, today announced that Gail Schulze has joined the company as chair and CEO. The company also announced several recent appointments to the Zosano leadership team, including Don Brown, ...
Nov 28, 2007
FREMONT, Calif.--(BUSINESS WIRE)--Zosano Pharma, Inc. announced today that it has closed enrollment of its Phase 2 clinical trial evaluating a parathyroid hormone (hPTH 1-34) transdermal microprojection delivery system to treat post menopausal women with osteoporosis who are at a high risk of bone fracture. This enrollment was completed ahead of...
Nov 15, 2007
FREMONT, Calif.--(BUSINESS WIRE)--Zosano Pharma, Inc., an emerging specialty pharmaceutical company focused on developing better pharmaceutical products using innovative drug delivery, has announced the receipt of the second half of its initial venture funding of $45 million, for a total investment of $90 million. Four venture capital firms, New...
Sep 27, 2007
FREMONT, Calif.--(BUSINESS WIRE)--Sept. 27, 2007--The Macroflux Corporation announced today that it has changed the name of the company to Zosano Pharma, Inc. "Our name change reflects the positive evolutionary steps the company is taking to advance our innovative transdermal microprojection delivery system technology," said M. Cory Zwerl...
May 31, 2007
Macroflux, an emerging specialty pharmaceutical company focused on the development of proprietary products, has named M. Cory Zwerling President and CEO of the company. “This is an exciting opportunity to lead Macroflux with a strong team, innovative product opportunities and high caliber Board,” said Mr. Zwerling. “The ...
Oct 10, 2006
Originally a group within ALZA Corporation, The Macroflux Corporation spin-out is being led byNomura Phase4 Ventures, a specialist investor in healthcare. The syndicate includes significant investments from New Enterprise Associates (NEA) and funds managed by HBM Partners. The$75M financing will enable the company to progress several product opp...
Page: FirstPrevious ...
8
= add release to Briefcase